This browser doesn't support Spotify Web Player. Switch browsers or download Spotify for your desktop.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

By PVI, PeerView Institute for Medical Education

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  1. 1.
    Josep Tabernero, MD, PhD - Optimizing Precision Medicine in Gastric Cancer Care11/21/2020
  2. 2.
    Jonathan A. Bernstein, MD - Chronic Spontaneous Urticaria From Diagnosis to Treatment: Unique Perspectives on Employing a Multidisciplinary and Patient-Centric Approach to Care11/18/2020
  3. 3.
    Kurt Schalper, MD, PhD - Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists11/17/2020
  4. 4.
    Professor David I. Marks - Antibody Therapy in Acute Leukemia: Understanding Clinical Considerations for Use in Conjunction With HSCT11/03/2020
  5. 5.
    George Plitas, MD - Making the Most of the New Era of Immuno-Oncology in TNBC: Essential Guidance for Surgeons on How to Maximize the Potential of Immunotherapies and Combinations in Advanced and Early-Stage Breast Cancer11/02/2020
  6. 6.
    Kenneth C. Kalunian, MD / Maureen A. McMahon, MD / Joan T. Merrill, MD - Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment to Provide Optimal Care for Each Patient10/26/2020
  7. 7.
    Leonard H. Calabrese, DO - Mapping the Path to Better Patient Outcomes in Rheumatoid Arthritis and Psoriatic Arthritis: Need-to-Know Information and Practical Guidance About JAK Inhibitors for Advanced Practice Providers09/28/2020
  8. 8.
    Heather L. McArthur, MD, MPH - Harnessing the Immune System in the Treatment of Triple-Negative Breast Cancer to Maximize Benefits to Patients: State of the Science, Key Trials, Implications for Practice, and Patient-Centric Clinical Decision-Making09/14/2020
  1. 9.
    Heather L. McArthur, MD, MPH - Chair's Take on Harnessing the Immune System in the Treatment of TNBC and Beyond: Where Are We Now and Where Are We Going Next?09/09/2020
  2. 10.
    Cedric "Jamie" Rutland, MD - Finding the Path to Improved Outcomes in Uncontrolled Persistent Asthma: Applying the Latest Clinical Evidence for Treatment Success09/03/2020
  3. 11.
    Josep Tabernero, MD, PhD - Optimizing Precision Medicine in Gastric Cancer Care: Essential Guidance on Translating Scientific Advances With Novel HER2-Targeted Therapies and Other Agents Into Current Clinical Practice08/31/2020
  4. 12.
    Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer08/19/2020
  5. 13.
    Kimberly Halla, MSN, FNP-C - Rethinking Patient Care in Endometrial and Cervical Cancer: How Nurses Can Lead the Targeted and Immunotherapeutic Revolution07/29/2020
  6. 14.
    "Brendon Stiles, MD - Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team"07/20/2020
  7. 15.
    Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer07/03/2020
  8. 16.
    Mitchell S. Cairo, MD - Achieving Consensus on Modern VOD/SOS Management: A Guide to Disease Recognition, Classification, and Treatment in Adults and Pediatric Patients07/01/2020
  9. 17.
    Brendon Stiles, MD - Chair's Take on Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team06/26/2020
  10. 18.
    Finding the Path to Clinically Meaningful Outcomes Among Expanding Treatment Options in Renal Cell Carcinoma06/24/2020
  11. 19.
    Richard S. Finn, MD - Chair’s Take: Review of the Latest HCC Therapy Advancements06/19/2020
  12. 20.
    Nadeem Riaz, MD, MSc - Deep Insight Into Immuno-Oncology: A Visual Exploration of Current and Emerging Pathways, Targets, and Biomarkers to Maximize the Potential of Cancer Immunotherapies06/05/2020
  13. 21.
    "Hope S. Rugo, MD, FASCO - Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Car"05/18/2020
  14. 22.
    Sagar Lonial MD, FACP - Changing Perspectives on Multiple Myeloma and ASCT: Clinical Decision-Making, New Evidence, and Expanding Therapeutic Options05/06/2020
  15. 23.
    Richard S. Finn, MD - Developing a Therapeutic Game Plan for the Management of Hepatocellular Carcinoma: Expert Insights From the Patient CaseBook04/29/2020
  16. 24.
    Professor Alan Irvine, MD, DSc - Addressing the Global Burden of Atopic Dermatitis: A Roadmap to Improving Diagnosis, Treatment, and Complete Patient Care04/27/2020
  17. 25.
    Roy F. Chemaly, MD, MPH, FIDSA, FACP - Changing the Paradigm of CMV Management: New Science and More Choices for Challenging Cases in the HCT Setting04/22/2020
  18. 26.
    Mitchell S. Cairo, MD - Following the Trail of Evidence in VOD Management: How Modern Risk Assessment, Diagnostic Principles, and Treatment Are Improving Care04/17/2020
  19. 27.
    Michael E. Wechsler, MD - The Evolving Landscape of Severe Asthma Management: Selecting Patients for Novel Treatment and Improving Adherence04/15/2020
  20. 28.
    Prithviraj Bose, MD / Jeanne M. Palmer, MD - State-of-the-Art Solutions for Myelofibrosis: The Intersection of JAK Inhibitors, Allogeneic Transplant, and Other Strategies for Patient Care04/10/2020
  21. 29.
    Arjun Balar, MD - Advancing Bladder Cancer Care With Novel Therapeutics: Where We Are Headed With Immunotherapy, Targeted, and Antibody Options04/08/2020
  22. 30.
    Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial04/01/2020
  23. 31.
    Praveen Akuthota, MD - Overcoming Challenges Associated With the Diagnosis and Management of EGPA: An Exploration of Novel Approaches03/06/2020
  24. 32.
    Marianne Davies , DNP, ACNP, AOCNP - Maximizing the Benefits and Minimizing the Risks of Cancer Immunotherapies in Everyday Oncology Practice: Need-to-Know Information and Practical Guidance for Oncology Nurses03/02/2020
  25. 33.
    John P. Leonard, MD - Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL02/26/2020
  26. 34.
    Toni K. Choueiri, MD - How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC02/19/2020
  27. 35.
    Andre H. Goy, MD - How I Think, How I Treat: BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond—Therapeutic Selection, Sequencing, and Next Steps02/17/2020
  28. 36.
    Miguel-Angel Perales, MD - Expanding Options for Prophylaxis and Treatment of Acute and Chronic GVHD: Mapping the Path to Better Patient Outcomes in Post-Transplant Care01/24/2020
  29. 37.
    Professor Peter Schmid, FRCP, MD, PhD - On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum01/22/2020
  30. 38.
    Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps01/22/2020
  31. 39.
    Reynold A. Panettieri, Jr., MD - Improving Outcomes in Uncontrolled Moderate-to-Severe Asthma: Choosing the Right Treatment for the Right Patient01/20/2020
  32. 40.
    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions01/17/2020
  33. 41.
    Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe12/27/2019
  34. 42.
    William J. Calhoun, MD, and Neil S. Skolnik, MD - Teaming Up to Overcome Challenges in Severe Asthma Management: The Role of Targeted Therapy in Personalized Care12/16/2019
  35. 43.
    Fernando J. Martinez, MD, MS - Winning Strategies for Diagnosing and Managing Chronic Obstructive Pulmonary Disease12/04/2019
  36. 44.
    Jonathan A. Bernstein, MD - Diagnosing and Managing Chronic Spontaneous Urticaria in Primary Care: Examining the Latest Clinical Evidence for Improved Patient Outcomes and Quality of Life11/29/2019
  37. 45.
    Stephen A. Strickland, MD, MSCI - The Oncology Team and Secondary AML: Conversations on New Science and Its Effect on Patient Care09/25/2019
  38. 46.
    Robert Z. Orlowski, MD, PhD - Driving Change in Multiple Myeloma: Updates on Novel Agent Classes and Next-Generation Therapeutics08/14/2019
  39. 47.
    Benjamin Levy, MD - Candid Conversations About NSCLC—Live From Chicago: Navigating Immunotherapies and Combinations in the Search for the Best Strategy for Each Patient08/09/2019
  40. 48.
    Ghassan Abou-Alfa, MD, MBA - ‘How I Think, How I Treat’—Embarking on a New Treatment Era in Hepatocellular Carcinoma: A Personal Take on Integrating Recent Evidence Into the Continuum of Care for Patients With HCC08/07/2019
  41. 49.
    Michael E. Wechsler, MD - Advances in the Treatment of Uncontrolled Persistent Asthma: Expert Insights in Personalizing Patient Care08/05/2019
  42. 50.
    John Allan, MD - Taking a New Look at Mantle Cell Lymphoma in the Era of Novel Agent Classes: From Innovative Concepts to Practical Applications of Evidence07/31/2019
  43. 51.
    Bruce Cree, MD, PhD, MAS - Examining Late-Breaking Data on Disease-Modifying Therapies for the Treatment of Multiple Sclerosis — An Update From Philadelphia07/29/2019
  44. 52.
    David F. McDermott, MD - Redefining the Management of Advanced RCC: An Expert Tumor Board on Rational Selection, Sequencing, and Combination of Targeted Agents and Immunotherapy07/26/2019
  45. 53.
    Nathan H. Fowler, MD - A MasterClass on Innovative Therapy in B-Cell Lymphoma: Evidence, Clinical Guidance, and Insights on the Future of Patient Care07/24/2019
  46. 54.
    Monica Kraft, MD - The Latest Evidence on Treatment for Uncontrolled Persistent Asthma: Breaking News From Dallas07/22/2019
  47. 55.
    Ezra Cohen, MD, FRCPSC, FASCO - Mapping Progress With Immune Checkpoint Inhibitors in Head and Neck Cancer: Expert Views on Immunotherapy as a Component of Multimodal Care07/19/2019
  48. 56.
    Edward J. Fox, MD, PhD - Personalizing Disease-Modifying Therapy for Multiple Sclerosis in the Era of Expanding Treatment Options and Potential Biomarkers07/17/2019
  49. 57.
    Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies07/10/2019
  50. 58.
    Jessica Donington, MD - The Expanding Role of Immunotherapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Thoracic Surgeons07/03/2019
  51. 59.
    Elizabeth A. Mittendorf, MD, PhD - On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum06/17/2019
  52. 60.
    Stephen V. Liu, MD - A New Era Has Begun in the Treatment of SCLC: Navigating Novel Therapeutic Options and Strategies for Improving Patient Outcomes06/14/2019
  53. 61.
    Richard S. Finn, MD / Laura M. Kulik, MD - Rethinking Care in Hepatocellular Carcinoma Amid Expanding Treatment Options: An Interdisciplinary Discussion05/24/2019
  54. 62.
    Robert Anders, MD, PhD - Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Implications for Pathologists at the Forefront of the Emerging Precision Immuno-Oncology Era05/20/2019
  55. 63.
    John Tesser, MD, FACP, FACR - Overcoming Challenges in the Management of Refractory Rheumatoid Arthritis: Expert Insight on the Clinical Potential of Novel Therapeutic Options05/13/2019
  56. 64.
    Justin F. Gainor, MD - New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine and Expand the Use of Cancer Immunotherapies and Combinations05/09/2019
  57. 65.
    Jason J. Luke, MD, FACP and Jennifer Wargo, MD, MMSc - Progress and Promise With Immunotherapy in Resectable Melanoma: Exploring New Evidence and Practical Issues With Checkpoint Inhibitors as Adjuvant Therapy05/06/2019
  58. 66.
    Benjamin Levy, MD - Refining Current Practice and Exploring New Frontiers in EGFR-Mutant NSCLC: Evolving Science, New Standards of Care, and Implications for Multidisciplinary Management05/03/2019
  59. 67.
    Jonathan Corren, MD and Paul Yamauchi, MD - Advances in the Management of Allergic and Inflammatory Diseases: Highlights From Washington, DC and San Francisco04/29/2019
  60. 68.
    Sagar Lonial, MD, FACP - Innovative Therapeutic Concepts for ASCT-Eligible Patients With Myeloma: Advancing Toward More Effective Care Across Treatment Settings04/22/2019
  61. 69.
    Mitchell S. Cairo, MD - Attacking the Clinical Problem of VOD/SOS in HCT Recipients: Insights on Pathophysiology, Diagnosis, and Treatment04/17/2019
  62. 70.
    Tanya Siddiqi, MD - Harnessing Recent Advances in CAR-T Cell Therapy for Leukemia and Lymphoma in the Era of Stem Cell Transplantation04/15/2019
  63. 71.
    Leonard H. Calabrese, DO - Rheumatology, Immunology, and Immuno-Oncology Intersect: Navigating the Complexities of Immune Checkpoint Inhibition, Autoimmunity, and Immune-Related Adverse Events: How Can Rheumatologists Help Minimize the Risks and Maximize the Benefits of Cancer Immunotherapies?04/12/2019
  64. 72.
    Mark A. Socinski, MD - Expanding Options and Difficult Choices in the Initial Treatment of Advanced NSCLC: How to Personalize Treatment Decisions in the Era of Immuno-Oncology and Combinations04/10/2019
  65. 73.
    Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance04/08/2019
  66. 74.
    Madan H. Jagasia, MBBS, MS, MMHC - Innovative Therapies in Post-Transplant GVHD: Personal Insights From the Patient CaseBook04/05/2019
  67. 75.
    Roy F. Chemaly, MD, MPH, FIDSA, FACP - Managing CMV in the New Era of Antiviral Therapy: Practical Considerations in the HCT Setting04/03/2019
  68. 76.
    Luciano J. Costa, MD, PhD - Exploring Clinical Decisions in the New Era of Myeloma Management: The Impact of Novel Platforms and Agent Classes Across the Spectrum of Care03/20/2019
  69. 77.
    Aaron Boster, MD - Improving Outcomes in Multiple Sclerosis Through the Practice of Shared Decision-Making in Disease-Modifying Therapy Selection03/13/2019
  70. 78.
    Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED03/11/2019
  71. 79.
    Richard S. Finn, MD - Breaking the Paradox: Expanding Options and New Questions in HCC Management—Mapping the Pathways to Better Patient Outcomes03/08/2019
  72. 80.
    Gregory Piazza, MD, MS - Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden02/22/2019
  73. 81.
    Arjun Balar, MD - Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes02/19/2019
  74. 82.
    Robert Anders, MD, PhD - The Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle: Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies02/13/2019
  75. 83.
    Barry Singer, MD - Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?01/18/2019
  76. 84.
    Randy Q. Cron, MD, PhD - Systemic Juvenile Idiopathic Arthritis: A Closer Look at the Burden on Patients and Caregivers From Diagnosis to Treatment01/16/2019
  77. 85.
    Jorge A. Marrero, MD, MS - Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes01/11/2019
  78. 86.
    Kurt Schalper, MD, PhD and Edward B. Garon, MD, MS - Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution12/14/2018
  79. 87.
    Edward B. Garon, MD, MS - Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice12/03/2018
  80. 88.
    Daniel Pallin, MD, MPH - Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy–Related Adverse Effects in the Emergency Department11/30/2018
  81. 89.
    Marilyn K. Glassberg, MD - Examining the IPF Patient’s Journey to Diagnosis, Appropriate Therapy, and Overall Individualized Care11/26/2018
  82. 90.
    Jonathan Corren, MD - A MasterClass on New Avenues in Asthma Management: Finding the Right Patients for Targeted Therapies11/21/2018
  83. 91.
    Mario Castro, MD - An Expert Analysis of New Data for Uncontrolled Persistent Asthma Treatments: Clinical Updates From Paris10/31/2018

Listen to PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast now.

Listen to PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast in full in the Spotify app